Cullen Frost Bankers Inc. Boosts Stock Position in Stryker Corporation $SYK

Cullen Frost Bankers Inc. lifted its position in Stryker Corporation (NYSE:SYK) by 3.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 66,826 shares of the medical technology company’s stock after purchasing an additional 2,245 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Stryker were worth $23,487,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Czech National Bank lifted its stake in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares during the last quarter. Davis R M Inc. lifted its stake in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after acquiring an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $1,216,000. Kepler Cheuvreux Suisse SA bought a new stake in shares of Stryker in the 3rd quarter valued at about $27,952,000. Finally, Daymark Wealth Partners LLC lifted its stake in shares of Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SYK. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Truist Financial reissued a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on Stryker in a research note on Friday, May 1st. Finally, Wells Fargo & Company lowered their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $395.48.

Stryker Trading Up 1.5%

SYK opened at $317.81 on Wednesday. The business has a 50 day simple moving average of $327.61 and a two-hundred day simple moving average of $350.70. The firm has a market capitalization of $121.84 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 1.97 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.